VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 41 filers reported holding VERONA PHARMA PLC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,227,802 | +35.0% | 934,221 | +75.1% | 0.01% | +33.3% |
| Q2 2023 | $11,277,852 | +101878.9% | 533,484 | -3.1% | 0.01% | 0.0% |
| Q1 2023 | $11,059 | +34.8% | 550,762 | +75.4% | 0.01% | +20.0% |
| Q4 2022 | $8,206 | -99.0% | 314,053 | +295.8% | 0.01% | – |
| Q3 2022 | $811,000 | +505.2% | 79,340 | +196.1% | 0.00% | – |
| Q1 2022 | $134,000 | +25.2% | 26,799 | +67.8% | 0.00% | – |
| Q4 2021 | $107,000 | +32.1% | 15,969 | +8.0% | 0.00% | – |
| Q3 2021 | $81,000 | +19.1% | 14,786 | +35.1% | 0.00% | – |
| Q3 2020 | $68,000 | – | 10,942 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |